Unlike most orthopedic market segments, trauma did not experience a V-shaped cliff and rebound during the pandemic. But that’s not to say it has been all smooth sailing for the trauma market.
China’s national volume-based procurement (VBP) policies for medical devices slashed prices for joint replacement, spine, trauma and sports medicine devices while generally making it more difficult for international companies to compete there.
The foot and ankle market experienced periodic slowdowns amid increasing competition. Some companies, like Smith+Nephew and Orthofix Medical, contended with supply constraints and other operational issues.
To get a sense of the overall trauma market, we looked at company reported trauma and extremity sales for the top four players in the space: DePuy Synthes, Stryker, Zimmer Biomet and Smith+Nephew. Together they represent 72% of the global trauma market. It is worth noting we’re presenting Zimmer Biomet’s SET category sales above, which contains a few other product categories but probably not enough to sway the trend line.
Despite the bumps in the market over the last four years, these companies’ trauma sales are growing right around the historical segment average of about 4%.
Stryker is the exception. It drove double-digit growth over this time period due to the integration of Wright Medical and a resulting renewed focus on innovating within core trauma.
Unlike most orthopedic market segments, trauma did not experience a V-shaped cliff and rebound during the pandemic. But that's not to say it has been all smooth sailing for the trauma market.
China's national volume-based procurement (VBP) policies for medical devices slashed prices for joint replacement, spine, trauma and sports medicine...
Unlike most orthopedic market segments, trauma did not experience a V-shaped cliff and rebound during the pandemic. But that’s not to say it has been all smooth sailing for the trauma market.
China’s national volume-based procurement (VBP) policies for medical devices slashed prices for joint replacement, spine, trauma and sports medicine devices while generally making it more difficult for international companies to compete there.
The foot and ankle market experienced periodic slowdowns amid increasing competition. Some companies, like Smith+Nephew and Orthofix Medical, contended with supply constraints and other operational issues.
To get a sense of the overall trauma market, we looked at company reported trauma and extremity sales for the top four players in the space: DePuy Synthes, Stryker, Zimmer Biomet and Smith+Nephew. Together they represent 72% of the global trauma market. It is worth noting we’re presenting Zimmer Biomet’s SET category sales above, which contains a few other product categories but probably not enough to sway the trend line.
Despite the bumps in the market over the last four years, these companies’ trauma sales are growing right around the historical segment average of about 4%.
Stryker is the exception. It drove double-digit growth over this time period due to the integration of Wright Medical and a resulting renewed focus on innovating within core trauma.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
